Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer - PROSELICA

Journal of Clinical Oncology

Volumn 35, Issue 28, 2017, Pages 3198-3206

  Eisenberger, Mario ^a   Hardy Bessard, Anne Claire ^b   Kim, Choung Soo ^e   Géczi, Lajos ^f   Ford, Daniel ^g   Mourey, Loïc ^c   Carles, Joan ⁱ   Parente, Phillip ^j   Font, Albert ^k   Kacso, Gabriel ^l   Chadjaa, Mustapha ^d   Zhang, Wenping ^d   Bernard, John ^m   De Bono, Johann ^h  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Medical Oncology   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d SANOFI   (France)

^e Asan Medical Center   (South Korea)

^f NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^g CITY HOSPITAL   (United Kingdom)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j MONASH UNIVERSITY   (Australia)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^m SANOFI   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TAXOID;

AGED; ALOPECIA; ANEMIA; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PAIN; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG SAFETY; EPIPHORA; FATIGUE; FEBRILE NEUTROPENIA; GLEASON SCORE; HEMATURIA; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOTOR NEUROPATHY; NAUSEA; NEUTROPENIA; OPEN STUDY; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROTOCOL COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SENSORY NEUROPATHY; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; KAPLAN MEIER METHOD; MULTICENTER STUDY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 85030155525     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.72.1076     Document Type: Article

References (15)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7-30, 2016
2. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
3. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004
4. Recine F, Sternberg CN: Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Transl Androl Urol 4:355-364, 2015
5. Vrignaud P, Sémiond D, Lejeune P, et al: Preclinical antitumor activity of cabazitaxel, a semisyn-thetic taxane active in taxane-resistant tumors. Clin Cancer Res 19:2973-2983, 2013
6. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
7. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate Cancer (version 3.2016). Fort Washington, PA, National Comprehensive Cancer Network, 2016
8. Mita AC, Denis LJ, Rowinsky EK, et al: Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15:723-730, 2009
9. Pivot X, Koralewski P, Hidalgo JL, et al: A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 19: 1547-1552, 2008
10. Schweizer MT, Antonarakis ES: Chemotherapy and its evolving role in the management of advanced prostate cancer. Asian J Androl 16:334-340, 2014
11. Center for Drug Evaluation and Research: NDA 20-1023 review: Cabazitaxel. Updated 2016. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201023s000Approv.pdf
12. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
13. National Cancer Institute: Common terminology criteria for adverse events (CTCAE), version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
14. James ND, Sydes MR, Clarke NW, et al: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163-1177, 2016
15. Sweeney CJ, Chen YH, Carducci M, et al: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373: 737-746, 2015